Allen Hicks is a trusted advisor that helps his clients execute complex strategic transactions, raise and invest capital, and navigate the securities laws. He draws upon a diverse skill set developed through more than 15 years of experience with a broad range of companies and industries to provide practical advice and insights for his clients.
He has represented public and privately held companies on strategic domestic and cross-border transactions, such as mergers and acquisitions (M&A), stock and asset purchases, divestitures, investments, tender offers, and restructurings. He also regularly advises public companies on Securities and Exchange Commission (SEC) reporting and disclosure obligations, New York Stock Exchange (NYSE) and NASDAQ listing requirements, corporate governance, board and shareholder matters, and capital markets offerings of equity and debt.
Over his career, he has represented clients in the U.S. and internationally across various industry sectors, including life sciences and healthcare, aerospace, defense, and government services (ADG), diversified industrials, financial services, insurance, hotel and lodging, real estate investment trusts (REITs), and technology. His clients range from large, global corporations to middle-market and emerging growth companies and investors to nonprofit organizations.
Before joining the firm, Allen served as Chief Counsel to U.S. Senate Majority Leader William H. Frist. Utilizing this federal government experience, Allen also advises clients from time to time on legislative and policy issues before the U.S. Congress.
Areas of Focus
Represented General Electric (NYSE: GE) Capital in the US$9bn sale of its healthcare financial services business to Capital One.
Represented Laboratory Corporation of America (NYSE: LH) in acquisitions of Genzyme Genetics, Medtox, Liposcience, and Sequenom.
Represented Lockheed Martin Corporation (NYSE: LMT) in multiple strategic acquisitions and more than US$11bn in debt securities offerings.
Represented REIT American Homes 4 Rent (NYSE: AMH) in more than US$1.3bn of common and preferred stock offerings, including a US$880m IPO.
Represented Dun & Bradstreet Corporation (NYSE: DNB) in its acquisitions of technology companies NetProspex and Avention.
Represented biotechnology company TESARO (NASDAQ: TSRO) in a US$201m convertible debt offering.
Represented Martek Biosciences Corporation (NASDAQ: MATK) in its US$1.1bn cross-border sale to Royal DSM, N.V.
Represented a nonprofit U.S. foundation in a reorganization of its holdings in a hotel and residential real estate resort development in Costa Rica.